Diabetic retinopathy (DR) is one of the main pathological features of the diabetes mellitus spectrum. It is estimated that in 2020 about 4 million people worldwide suffered from blindness or visual impairment caused by DR. Many patients cannot access treatment, mostly because of high costs, while others discontinue it prematurely due to the high number of intravitreal administrations required, or the occurrence of ocular complications, or discomfort in quality of life.
Emerging drugs for the treatment of diabetic retinopathy
Striglia, Elio;Caccioppo, Andrea;Reibaldi, Michele;Porta, Massimo
2020-01-01
Abstract
Diabetic retinopathy (DR) is one of the main pathological features of the diabetes mellitus spectrum. It is estimated that in 2020 about 4 million people worldwide suffered from blindness or visual impairment caused by DR. Many patients cannot access treatment, mostly because of high costs, while others discontinue it prematurely due to the high number of intravitreal administrations required, or the occurrence of ocular complications, or discomfort in quality of life.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Published manuscript Emerging drugs for the treatment of diabetic retinopathy.pdf
Open Access dal 06/08/2021
Descrizione: Articolo principale
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
772.84 kB
Formato
Adobe PDF
|
772.84 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
